Observational studyScientific reports2025
Subgroup analysis of treatment pathways and clinical outcomes in Hodgkin lymphoma in Latin America from the retrospective B-HOLISTIC study.
Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03327571 (An International, Multi-centre, Non-interventional Retrospective Study to Describe Treatment Pathways, Outcomes, and Resource Use in Patients With Classical Hodgkin Lymphoma), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An International, Multi-centre, Non-interventional Retrospective Study to Describe Treatment Pathways, Outcomes, and Resource Use in Patients With Classical Hodgkin Lymphoma (B-HOLISTIC)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Real-world data on Hodgkin lymphoma (HL) treatment and outcomes in Latin America are limited. The B-HOLISTIC study (2010-2013) retrospectively assessed treatment patterns and outcomes in patients with stage IIB-IV classical HL receiving frontline chemotherapy (frontline cHL) or relapsed/refractory HL (RRHL) in regions outside Europe and North America. This subgroup analysis presents findings from patients enrolled from treatment centers in Argentina, Colombia, and Mexico. The primary endpoint was progression-free survival (PFS) in patients with RRHL. Other endpoints included overall survival (OS), best clinical response, and treatment patterns. In Latin America (frontline cHL: 344; RRHL: 92), the most common frontline regimen was ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). In patients with RRHL receiving salvage chemotherapy (92.4%), common regimens were ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin) and ICE (ifosfamide, carboplatin, etoposide). Overall, 68.2% of eligible patients with RRHL underwent stem cell transplantation (SCT). Median PFS and OS in the RRHL group was 20.2 and 87 months, respectively; the 5-year PFS rate was 27.1%. Survival outcomes were improved in patients who underwent SCT than those without SCT. Median PFS and OS in the cHL group were not reached. These data demonstrated that while real-world HL treatment in Latin America was consistent with guidelines during the study period, clinical outcomes were suboptimal compared with developed regions. This emphasizes the need for novel therapies and improved progression to SCT in this patient population. These findings may offer valuable insights and serve as a reference for future studies in this region. ClinicalTrials.gov Identifier: NCT03327571, registered October 31, 2017.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.